We will be looking for more color around the company’s organic growth prospects.
But we still think shares could ultimately rebound.
Positive data from drug study help boost stock.
It's making progress on refranchising bakery-cafes.
First-quarter revenues missed and second-quarter and full-year guidance was lowered.
Shares are up 40% this year.
We're buying more shares of Actavis, shrinking Red Hat.
After these results, the company is well positioned to continue beating expectations.
The company beat solidly on the top and bottom lines.
Determining trends requires looking closer at the best- and worst-performing stocks before making a judgment.